The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Evolution of Systemic Therapy for Hepatocellular Carcinoma
Hepatology. 2020 May 7. doi: 10.1002/hep.31306. Online ahead of print.
Richard S Finn1, Andrew X Zhu23
Author information
1Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA, Los Angeles, United States.
2Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114-2696, United States.
3Jiahui International Cancer Center, Jiahui Health, Shanghai, China.
Abstract
Despite being one of the leading causes of cancer death globally, hepatocellular carcinoma (HCC) has historically not been the focus of novel drug development. In the past several years that has changed with the results from a number of hallmark phase 3 studies in advanced HCC. In HCC, immune-oncology approaches have garnered much attention; there is still a need to better understand criteria for patient selection and to optimize combination strategies to maximize the potential of these approaches. The next generation of studies will aim at translating our increased understanding of tumor biology into clinical trial design.